Biomarkers in rare diseases

Public Health Genomics

Volumn 16, Issue 6, 2013, Pages 313-321

  Ferlini, A ^a   Scotton, C ^a   Novelli, G ^b,c  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

Biomarkers; Diagnostics; Genetics; Genomics; Mendelian; Omics; Proteomics; Rare diseases; Therapies; Transcriptomics

Indexed keywords

BIOLOGICAL MARKER; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DYSTROPHIN; GELATINASE B; MICRORNA; TENASCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BIOMICS; DNA METHYLATION; DUCHENNE MUSCULAR DYSTROPHY; EMERY DREIFUSS MUSCULAR DYSTROPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGENETICS; FRIEDREICH ATAXIA; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOASSAY; MARFAN SYNDROME; MASS SPECTROMETRY; MEDICAL ETHICS; NEXT GENERATION SEQUENCING; PARALLEL OMICS; PERSONALIZED MEDICINE; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; QUANTITATIVE ANALYSIS; RARE DISEASE; RNA SEQUENCE; SPINAL MUSCULAR ATROPHY; VALIDITY; METABOLISM; PROGNOSIS; REVIEW;

BIOLOGICAL MARKERS; HUMANS; INDIVIDUALIZED MEDICINE; PROGNOSIS; RARE DISEASES;

EID: 84899907896     PISSN: 16624246     EISSN: 16628063     Source Type: Journal    
DOI: 10.1159/000355938     Document Type: Article

References (26)

1. Beck M: 'Rare' and 'Ultra Rare Diseases'. Outlook Develop Drugs 2012; 1:e107.
2. Roubertoux PL, de Vries PJ: From molecules to behavior: lessons from the study of rare genetic disorders. Behav Genet 2011; 41: 341-348.
3. Pavlovich CP, Schmidt LS: Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer 2004; 4: 381-393.
4. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
5. Finkel RS, Crawford TO, Swoboda KJ, Kaufmann P, Juhasz P, Li X, Guo Y, Li RH, Trachtenberg F, Forrest SJ, Kobayashi DT, Chen KS, Joyce CL, Plasterer T; Pilot Study of Biomarkers for Spinal Muscular Atrophy Trial Group: Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical study. PLoS One 2012; 7:e35462.
6. Mitrpant C, Fletcher S, Wilton SD: Personalised genetic intervention for Duchenne muscular dystrophy: antisense oligomers and exon skipping. Curr Mol Pharmacol 2009; 2: 110-121.
7. Ma Q, Lu AY: Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 2011; 63: 437-459.
8. European Medicines Agency: Qualification opinion of Alzheimer's disease novel methodologies/ biomarkers for PET amyloid imaging (positive/negative) as a biomarker for enrichment for use-in predementia AD clinical trials. 2011. http://www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2011/12/WC500118364.pdf
9. Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, Chen R, Miriami E, Karczewski KJ, Hariharan M, Dewey FE, Cheng Y, Clark MJ, Im H, Habegger L, Balasubramanian S, O'Huallachain M, Dudley JT, Hillenmeyer S, Haraksingh R, Sharon D, Euskirchen G, Lacroute P, Bettinger K, Boyle AP, Kasowski M, Grubert F, Seki S, Garcia M, Whirl-Carrillo M, Gallardo M, Blasco MA, Greenberg PL, Snyder P, Klein TE, Altman RB, Butte AJ, Ashley EA, Gerstein M, Nadeau KC, Tang H, Snyder M: Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012; 148: 1293-1307.
10. EMEA: Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. 2006. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/ 2009/09/WC500002880.pdf.
11. European Medicines Agency: ICH guideline E16 genomic biomarkers related to drug response: context, structure and format of qualification submissions. 2009. http://www.ema. europa.eu/docs/en-GB/document-library/ Scientific-guideline/2010/09/WC500097060. pdf.
12. McCormack P, Woods S, Aartsma-Rus A, Hagger L, Herczegfalvi A, Heslop E, Irwin J, Kirschner J, Moeschen P, Muntoni F, Ouillade MC, Rahbek J, Rehmann-Sutter C, Rouault F, Sejersen T, Vroom E, Straub V, Bushby K, Ferlini A: Guidance in social and ethical issues related to clinical, diagnostic care and novel therapies for hereditary neuromuscular rare diseases: 'translating' the translational. PLoS Curr 2013; 10: 5.
13. Hwang CS, Liu GT, Chang MD, Liao IL, Chang HT: Elevated serum autoantibody against high mobility group box 1 as a potent surrogate biomarker for amyotrophic lateral sclerosis. Neurobiol Dis 2013; 58: 13-18.
14. Franken R, den Hartog AW, de Waard V, Engele L, Radonic T, Lutter R, Timmermans J, Scholte AJ, van den Berg MP, Zwinderman AH, Groenink M, Mulder BJ: Circulating transforming growth factor-β as a prognostic biomarker in Marfan syndrome. Int J Cardiol 2013; 168: 2441-2446.
15. Nadarajah VD, van Putten M, Chaouch A, Garrood P, Straub V, Lochmüller H, Ginjaar HB, Aartsma-Rus AM, van Ommen GJ, den Dunnen JT, 't Hoen PA: Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul Disord 2011; 21: 569-578.
16. Wen Q, Huang LT, Luo N, Wang YT, Li XY, Mao HP, Zhang L, Dong XQ, Yu XQ: Proteomic profiling identifies haptoglobin as a potential serum biomarker for steroid-resistant nephrotic syndrome. Am J Nephrol 2012; 36: 105-113.
17. Mizuno H, Nakamura A, Aoki Y, Ito N, Kishi S, Yamamoto K, Sekiguchi M, Takeda S, Hashido K: Identification of muscle-specific microRNAs in serum of muscular dystrophy animal models: promising novel blood-based markers for muscular dystrophy. PLoS One 2011; 6:e18388.
18. Eisenberg I, Alexander MS, Kunkel LM: miRNAS in normal and diseased skeletal muscle. J Cell Mol Med 2009; 13: 2-11.
19. Megiorni F, Cialfi S, Cimino G, De Biase RV, Dominici C, Quattrucci S, Pizzuti A: Elevated levels of miR-145 correlate with SMAD3 down-regulation in Cystic Fibrosis patients. J Cyst Fibros 2013;pii:S1569-1993(13)00043-X.
20. Evans-Galea MV, Carrodus N, Rowley SM, Corben LA, Tai G, Saffery R, Galati JC, Wong NC, Craig JM, Lynch DR, Regner SR, Brocht AF, Perlman SL, Bushara KO, Gomez CM, Wilmot GR, Li L, Varley E, Delatycki MB, Sarsero JP: FXN methylation predicts expression and clinical outcome in Friedreich ataxia. Ann Neurol 2012; 71: 487-497.
21. Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, Li K, Choi J, Vuga LJ, Lindell KO, Klesen M, Zhang Y, Gibson KF: Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185: 67-76.
22. Niebroj-Dobosz I, Madej-Pilarczyk A, Marchel M, Sokołowska B, Hausmanowa-Petrusewicz I: Circulating tenascin-C levels in patients with dilated cardiomyopathy in the course of Emery-Dreifuss muscular dystrophy. Clin Chim Acta 2011; 412: 1533-1538.
23. Sedic M, Kraljevic Pavelic S, Cindric M, Vissers JP, Peronja M, Josic D, Cuk M, Fumic K, Pavelic K, Baric I: Plasma biomarker identification in S-adenosylhomocysteine hydrolase deficiency. Electrophoresis 2011; 32: 1970-1975.
24. Kistler AD, Siwy J, Breunig F, Jeevaratnam P, Scherl A, Mullen W, Warnock DG, Wanner C, Hughes DA, Mischak H, Wüthrich RP, Serra AL: A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy. PLoS One 2011; 6:e20534.
25. Kinali M, Arechavala-Gomeza V, Cirak S, Glover A, Guglieri M, Feng L, Hollingsworth KG, Hunt D, Jungbluth H, Roper HP, Quinlivan RM, Gosalakkal JA, Jayawant S, Nadeau A, Hughes-Carre L, Manzur AY, Mercuri E, Morgan JE, Straub V, Bushby K, Sewry C, Rutherford M, Muntoni F: Muscle histology vs MRI in Duchenne muscular dystrophy. Neurology 2011; 25: 76: 346-353.
26. Kotelnikova E, Shkrob MA, Pyatnitskiy MA, Ferlini A, Daraselia N: Novel approach to meta-analysis of microarray datasets reveals muscle remodeling-related drug targets and biomarkers in Duchenne muscular dystrophy. PLoS Comput Biol 2012; 8:e1002365.